Recently,the therapy for malignant tumor has entered the era of individualized molecular targeted therapy.Targeted therapy could significantly improve survival,reduce chemotherapy related toxicity,improve quality of life.Precise individualized therapy is based on accurate diagnosis of molecular targets.Therefore,it is very important and urgent for China to establish normative training system for laboratory technicians and uniform management of testing methods.The most ideal samples for testing are primary tumor tissues (except malignant hematologic diseases),but the tumor samples in a large amount of patients could not be obtained for some reasons.Therefore,exploring other originated samples such as blood and malignant body cavity effusion has attracted considerable attention.Molecular epidemiology study of gene mutations in tumor patients is also one of the most important areas for individualized targeted therapy.

High-dose therapy (HDT) combined with autologous hematopoietic stem cell transplantation (AHSCT) is a standard treatment for relapsed or refractory aggressive lymphoma. However, the role of HDT/AHSCT in the first-line treatment of lymphoma remains controversial, and related issues about its application in different subtypes of lymphoma should be addressed. This article brief-ly reviewed the clinical progress in AHSCT for malignant lymphoma treatment.

Over the past years, the incidence of lymphoma has been increasing, which has become one of the most common cancers around the world.The survival of lymphoma patients has been significantly improved due to advances of therapeutic methods such as new chemotherapy regimens, monoclonal antibodies and small molecular targeted drugs.However, the number of patients with relapsed/refractory lymphoma still account for a large proportion.It is of great significance to find new ways to treat these patients.Cellular immunotherapy could kill tumor cells by causing specific and effective antitumor immune response.Remarkable advances have been made in immunotherapy, such as adoptive immunotherapy, immune checkpoint inhibitors and immunomodulation therapy, for relapsed/refractory lymphoma patients, which will gradually open a new era in the treatment of lymphoma.

Cancer has become a great menace to public health in China.Tumor markers play a unique role in diagnosis and treatment of cancer.However,there lacks a systematic evidence-based guideline in conformity with national conditions on clinical application of tumor markers.Recommendation for the use of the tumor markers in clinical practice will guide the appropriate usage of tumor markers and exhibit profound positive impact on their clinical application in China.

Hodgkin lymphoma (HL) is a type of curable tumor. The treatment strategy of HL is based on staging and risk of recurrence. With the continuous optimization of combined treatment mode, the prognosis of HL has been greatly improved. The predictive value of the prognostic models widely used in HL is lower than before. Therefore, exploring new prognostic factors and enriching existing prognostic models to provide patients with precise and individualized treatment is an important research direction for HL. This article reviews the progress of prognostic factors for HL in recent years.

Carcinoma, Non-Small-Cell Lung ; therapy ; Drug Delivery Systems ; trends ; Drug Therapy ; trends ; Humans

Humans ; Lymphoma, T-Cell, Peripheral ; diagnosis ; therapy ; Translational Medical Research

Cancer is a serious threat to human health with high morbidity and high mortality , using vitro tumor diagnostic reagents can improve the level of diagnosis and treatment.In order to develop the value of in vitro tumor diagnostic reagents in clinical use , this article would analyze “in vitro diagnostic reagents technical guidelines for clinical research” ,“in vitro diagnostic reagents registration” and other laws and regulations ,as well as the development of research in domestic and foreign.To discuss the clinical scheme design and development trend of in vitro tumor diagnostic reagents.

The fusion gene between echinoderm microtubule-associated protein-like 4 (EML4) and anaplastic lymphoma kinase (ALK) has recently been identified as a new molecular target of non-small cell lung cancers (NSCLC). Stage Ⅰ and stage Ⅱ clinical trials have observed remarkably clinical efficacy of ALK inhibitors in NSCLC patients harboring EML4-ALK translocations, with response rates exceeding ＞ 80%. Investigation of EML4-ALK's biological functions and its correlation with clinical characteristics may shed some light on a new treatment strategy for NSCLC.

Detection of prostate specific antigen (PSA) is the most commonly used screening method for prostate cancer. However, many studies have found that the false positive rate and false negative rate of PSA detection for prostate cancer screening are very high, which easily leads to the overuse of PSA detection. Autoantibodies appear at the early stage of cancer, accompany the occurrence and development of prostate cancer. Autoantibodies have a long half-life and are easy to detect. Existing studies have found that autoantibodies can be used in the diagnosis of prostate cancer, and correlated with some prognostic indicators such as Gleason grade and overall survival (OS) of prostate cancer patients. This paper summarized 8 studies on the role of single autoantibody in the diagnosis and prognosis of prostate cancer. Most of the reported single autoantibodies have better diagnostic performance than PSA, and combined application could improve the diagnostic performance. Some autoantibodies are related to a poor prognosis of prostate cancer.